Pharma major, Lupin’s subsidiary, Lupin Pharmaceuticals Inc, has launched its Fenofibrtae tablets, 48 mg and 145 mg strengths in the United States. The company has earlier received final approval for the same from the US Food and Drug Administration (USFDA).
Lupin’s Fenofibrtae tablets are the AB rated generic equivalent of Abbott’s TRICOR tablets and are indicated for primary Hypercholesterolemia or Mixed Dyslipidemia and Severe Hypertriglyceridemia. Abbott’s TRICOR tablets 48 mg and 145 mg had sales of $1.26 billion as per IMS Health, June, 2012.
Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
